Skip to main content
. 2017 May 12;96(19):e6769. doi: 10.1097/MD.0000000000006769

Figure 2.

Figure 2

Kaplan–Meier analysis of overall survival in a phase II study of FOLFIRINOX as second-line chemotherapy for unresectable pancreatic cancer after gemcitabine-based chemotherapy failure. The median survival was 9.8 months (95% confidence interval, 6.4–13.1). No patient data were censored.